TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma
Brief Summary: Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.


Options:
A: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
B: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
D: Arm Label: Pertuzumab + Trastuzumab + Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Pertuzumab, Drug: Trastuzumab, Drug: Docetaxel | Arm Label: Placebo + Trastuzumab + Docetaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Trastuzumab, Drug: Docetaxel | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma
Brief Summary: Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.


Options:
A: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
B: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel | Arm Label: irinotecan; Type: EXPERIMENTAL; Interventions: Drug: Irinotecan | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): paclitaxel | Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): irinotecan
D: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Randomized, Double-blind Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease (COPD). This study will be 54 weeks in duration; a 52-week double-blind treatment period and 2 week follow-up phone call, following a 12 week lead-in study. All patients will be randomized from the lead-in study at one of two doses of aclidinium.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: ADVAIR DISKUS 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: ADVAIR DISKUS 250/50 mg BID | Arm Label: Serevent 50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: SEREVENT 50 mcg BID | Intervention Type: DRUG; Name: ADVAIR DISKUS 250/50 mg BID; Assigned to Arm(s): ADVAIR DISKUS 250/50 mcg BID | Intervention Type: DRUG; Name: SEREVENT 50 mcg BID; Assigned to Arm(s): Serevent 50 mcg BID
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Infant Formula With Bovine Milk Osteopontin on Infant Growth, Health and Immune functions-a Double-blind Randomized Trial
Brief Summary: The specific objectives of this study are to evaluate the effects of bovine milk osteopontin added to infant formula on infant growth, health and immune functions.


Options:
A: Arm Label: Amino Acid Formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amino Acid Formula | Arm Label: EHCF; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Extensively Hydrolyzed Casein Formula | Arm Label: EHCF + LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG, Dietary Supplement: Extensively Hydrolyzed Casein Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG; Assigned to Arm(s): EHCF + LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Extensively Hydrolyzed Casein Formula; Assigned to Arm(s): EHCF, EHCF + LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Amino Acid Formula; Assigned to Arm(s): Amino Acid Formula
B: Arm Label: Standard infant formula; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Standard infant formula | Arm Label: Protein-reduced whey formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced whey formula | Arm Label: Protein-reduced α-lactalbumin formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein-reduced α-lactalbumin formula | Arm Label: Breast-feeding; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced α-lactalbumin formula; Assigned to Arm(s): Protein-reduced α-lactalbumin formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein-reduced whey formula; Assigned to Arm(s): Protein-reduced whey formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Standard infant formula; Assigned to Arm(s): Standard infant formula
C: Arm Label: Reference group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard infant formula | Arm Label: Formula with 50% Osteopontin; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula supplemented with bovine milk Osteopontin | Arm Label: Formula with 100% Osteopontin; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula supplemented with bovine milk Osteopontin | Intervention Type: OTHER; Name: Infant formula supplemented with bovine milk Osteopontin; Assigned to Arm(s): Formula with 100% Osteopontin, Formula with 50% Osteopontin | Intervention Type: OTHER; Name: Standard infant formula; Assigned to Arm(s): Control formula
D: Arm Label: parenteral nutrition solution; Type: OTHER; Interventions: Drug: Ped3CB | Intervention Type: DRUG; Name: Ped3CB; Assigned to Arm(s): parenteral nutrition solution

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Cognitive Behavioral Analysis System of Psychotherapy (CBASP) and System of Supportive Psychotherapy (SYSP) for Early Onset Chronic Depression
Brief Summary: The purpose of this study is to compare the efficacy of the Cognitive Behavioural Analysis System of Psychotherapy (CBASP) with the non-specific System of Supportive Psychotherapy (SYSP)in early onset chronically depressives.


Options:
A: Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Continuation phase cognitive therapy, Behavioral: Acute phase cognitive therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Continuation phase pill placebo, Behavioral: Acute phase cognitive therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuation phase fluoxetine, Behavioral: Acute phase cognitive therapy | Intervention Type: BEHAVIORAL; Name: Continuation phase cognitive therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Continuation phase fluoxetine; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Continuation phase pill placebo; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Acute phase cognitive therapy; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
D: Arm Label: CBASP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Analysis System of Psychotherapy | Arm Label: SYSP; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: System of Supportive Psychotherapy | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Analysis System of Psychotherapy; Assigned to Arm(s): CBASP | Intervention Type: BEHAVIORAL; Name: System of Supportive Psychotherapy; Assigned to Arm(s): SYSP

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Brief Summary: The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full etc.)


Options:
A: Arm Label: Silodosin; Type: EXPERIMENTAL; Interventions: Drug: Silodosin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Silodosin; Assigned to Arm(s): Silodosin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo capsule | Arm Label: Tadalafil 5 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Tadalafil 5 mg | Arm Label: Tamsulosin 0.4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tadalafil 5 mg; Assigned to Arm(s): Tadalafil 5 milligram (mg) | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin 0.4 mg | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo
C: Arm Label: Silodosin; Type: EXPERIMENTAL; Interventions: Drug: Silodosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Silodosin; Assigned to Arm(s): Silodosin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Silodosin; Type: EXPERIMENTAL; Interventions: Drug: Silodosin | Arm Label: Tamsulosin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin; Assigned to Arm(s): Silodosin | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Brief Summary: The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full etc.)


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo capsule | Arm Label: Tadalafil 5 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Tadalafil 5 mg | Arm Label: Tamsulosin 0.4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tadalafil 5 mg; Assigned to Arm(s): Tadalafil 5 milligram (mg) | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin 0.4 mg | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
C: Arm Label: 5 milligrams (mg) Tadalafil; Type: EXPERIMENTAL; Interventions: Drug: Tadalafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): 5 milligrams (mg) Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Viagra; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind Randomized Controlled Trial of Recombinant Human Platelet Derived Growth Factor-BB Gel (Regranex Gel®) Versus Hydrogel (Duoderm Hydrogel®) for Healing of MARTORELL's Hypertensive Leg Ulcers. ERAN Trial.
Brief Summary: Background: No medical treatment has proved its efficacy for the treatment of hypertensive leg ulcers in a well designed trial.

Primary aim of the study: to compare the rate of healing in hypertensive leg ulcers treated with becaplermin gel (Regranex Gel®) daily application versus the application of the same quantity of an hydrogel (Duoderm Hydrogel™), corresponding to the excipient of becaplermin gel.

Method: Ambulatory or hospitalized patients presenting with an hypertensive leg ulcer, were randomized to receive either a daily application of becaplermin gel or hydrogel during 8 weeks. At week 8, a pinch graft was proposed to patients whom the ulcer has not healed.

Primary aim of the study: Complete closure at week 8

Secondary aims: percentage of wound area reduction at week 8, complete closure at week 12, pain and quality of life during treatment

Study hypothesis: becaplermin gel may promote the healing of hypertensive leg ulcers and be an alternative medical treatment to the skin graft usually proposed


Options:
A: Arm Label: HP802-247 plus compression therapy; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: HP802-247 Vehicle plus compression therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: HP802-247 Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 plus compression therapy | Intervention Type: OTHER; Name: HP802-247 Vehicle; Assigned to Arm(s): HP802-247 Vehicle plus compression therapy
B: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle
C: Arm Label: A - Low Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: B - Low Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: C - High Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: D - High Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: E - Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (Vehicle) | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): A - Low Q7D, B - Low Q14D, C - High Q7D, D - High Q14D | Intervention Type: BIOLOGICAL; Name: Placebo (Vehicle); Assigned to Arm(s): E - Vehicle
D: Arm Label: becaplermin gel; Type: EXPERIMENTAL; Interventions: Drug: becaplermin gel | Arm Label: Duoderm Hydrogel™; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duoderm Hydrogel™ | Intervention Type: DRUG; Name: becaplermin gel; Assigned to Arm(s): becaplermin gel | Intervention Type: DRUG; Name: Duoderm Hydrogel™; Assigned to Arm(s): Duoderm Hydrogel™

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vaasa Childhood Obesity Primary Prevention Study
Brief Summary: This study aims to prevent childhood obesity with early life (pregnancy) intensified counselling. The recruited intervention group is pregnant mothers who are at risk to get gestational diabetes. Lifestyle intervention (nutritional and physical activity) begins during pregnancy in maternity clinics and continues in child wellfare clinics until the child is 5 years of age.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Vaasa Childhood Obesity Primary Prevention Study | Intervention Type: BEHAVIORAL; Name: Vaasa Childhood Obesity Primary Prevention Study; Assigned to Arm(s): Lifestyle counseling
B: Arm Label: MOVI-KIDS Program; Type: EXPERIMENTAL; Interventions: Behavioral: MOVI-KIDS | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MOVI-KIDS; Assigned to Arm(s): MOVI-KIDS Program
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: physical activity; Assigned to Arm(s): Intervention
D: Arm Label: Tools for Teen Moms Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tools for Teen Moms | Arm Label: MIHP standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tools for Teen Moms; Assigned to Arm(s): Tools for Teen Moms Intervention Group

Answer: A